| Teresa Carol Heatly, MD | |
|
5151 E Broadway Rd Ste 107, Mesa, AZ 85206-1346 | |
| (480) 290-7000 | |
| (480) 325-3461 |
| Full Name | Teresa Carol Heatly |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 35 Years |
| Location | 5151 E Broadway Rd Ste 107, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366466039 | NPI | - | NPPES |
| 23465 | Other | AZ | LICENSE |
| 318677 | Medicaid | AZ | |
| 100258873 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 3600-320 (Wisconsin) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 23465 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Vincent Hospital | Green bay, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Vincent Hospital-hospital Sisters-third Order Of St Francis | 5799694675 | 562 |
News Archive
A research team led by Dr. Xiang David Li from the Department of Chemistry at The University of Hong Kong, in collaboration with scientists from Tsinghua University in China, The Rockefeller University, and The University of Texas MD Anderson Cancer Center in the United States, developed the first chemical inhibitors against a novel therapeutic target for treatment of acute myeloid leukemia, a fast-growing cancer of bone marrow and blood cells.
The coronavirus disease (COVID-19) has left many countries grappling with high infection rates. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has negatively impacted societies and economies. Now though, many countries are starting to lift restrictions to prepare for a "new normal."
Bioness Inc., a leading neuromodulation company, announced today two agreements to distribute new devices for patients experiencing neurological impairment. Through the agreements with Performance Enterprises and Aretech™, LLC, Bioness is now distributing the Dynavision D2™ Visuomotor Training System and the ZeroG™ Overground Gait and Balance Training System to rehabilitation centers and hospitals.
To detect "silent" or new cardiac abnormalities, all patients hospitalized for stroke should receive continuous cardiac rhythm monitoring (telemetry) for at least the first 24 hours after the stroke is detected, according to a Loyola University Health System study presented at the American Stroke Association's International Stroke Conference 2006.
Critical Outcome Technologies Inc. today announced positive results from the first phase of its HIV integrase inhibitor discovery program. These results provide novel intellectual property to the Company and further validation of the CHEMSAS® drug discovery technology.
› Verified 6 days ago
| Entity Name | St. Nicholas Hospital-sisters Of The Third Order Of St Francis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275799413 PECOS PAC ID: 8325931652 Enrollment ID: O20040202001172 |
News Archive
A research team led by Dr. Xiang David Li from the Department of Chemistry at The University of Hong Kong, in collaboration with scientists from Tsinghua University in China, The Rockefeller University, and The University of Texas MD Anderson Cancer Center in the United States, developed the first chemical inhibitors against a novel therapeutic target for treatment of acute myeloid leukemia, a fast-growing cancer of bone marrow and blood cells.
The coronavirus disease (COVID-19) has left many countries grappling with high infection rates. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has negatively impacted societies and economies. Now though, many countries are starting to lift restrictions to prepare for a "new normal."
Bioness Inc., a leading neuromodulation company, announced today two agreements to distribute new devices for patients experiencing neurological impairment. Through the agreements with Performance Enterprises and Aretech™, LLC, Bioness is now distributing the Dynavision D2™ Visuomotor Training System and the ZeroG™ Overground Gait and Balance Training System to rehabilitation centers and hospitals.
To detect "silent" or new cardiac abnormalities, all patients hospitalized for stroke should receive continuous cardiac rhythm monitoring (telemetry) for at least the first 24 hours after the stroke is detected, according to a Loyola University Health System study presented at the American Stroke Association's International Stroke Conference 2006.
Critical Outcome Technologies Inc. today announced positive results from the first phase of its HIV integrase inhibitor discovery program. These results provide novel intellectual property to the Company and further validation of the CHEMSAS® drug discovery technology.
› Verified 6 days ago
| Entity Name | St Vincent Hospital-hospital Sisters-third Order Of St Francis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285613638 PECOS PAC ID: 5799694675 Enrollment ID: O20080620000423 |
News Archive
A research team led by Dr. Xiang David Li from the Department of Chemistry at The University of Hong Kong, in collaboration with scientists from Tsinghua University in China, The Rockefeller University, and The University of Texas MD Anderson Cancer Center in the United States, developed the first chemical inhibitors against a novel therapeutic target for treatment of acute myeloid leukemia, a fast-growing cancer of bone marrow and blood cells.
The coronavirus disease (COVID-19) has left many countries grappling with high infection rates. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has negatively impacted societies and economies. Now though, many countries are starting to lift restrictions to prepare for a "new normal."
Bioness Inc., a leading neuromodulation company, announced today two agreements to distribute new devices for patients experiencing neurological impairment. Through the agreements with Performance Enterprises and Aretech™, LLC, Bioness is now distributing the Dynavision D2™ Visuomotor Training System and the ZeroG™ Overground Gait and Balance Training System to rehabilitation centers and hospitals.
To detect "silent" or new cardiac abnormalities, all patients hospitalized for stroke should receive continuous cardiac rhythm monitoring (telemetry) for at least the first 24 hours after the stroke is detected, according to a Loyola University Health System study presented at the American Stroke Association's International Stroke Conference 2006.
Critical Outcome Technologies Inc. today announced positive results from the first phase of its HIV integrase inhibitor discovery program. These results provide novel intellectual property to the Company and further validation of the CHEMSAS® drug discovery technology.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Teresa Carol Heatly, MD 5151 E Broadway Rd Ste 107, Mesa, AZ 85206-1346 Ph: (480) 290-7000 | Teresa Carol Heatly, MD 5151 E Broadway Rd Ste 107, Mesa, AZ 85206-1346 Ph: (480) 290-7000 |
News Archive
A research team led by Dr. Xiang David Li from the Department of Chemistry at The University of Hong Kong, in collaboration with scientists from Tsinghua University in China, The Rockefeller University, and The University of Texas MD Anderson Cancer Center in the United States, developed the first chemical inhibitors against a novel therapeutic target for treatment of acute myeloid leukemia, a fast-growing cancer of bone marrow and blood cells.
The coronavirus disease (COVID-19) has left many countries grappling with high infection rates. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has negatively impacted societies and economies. Now though, many countries are starting to lift restrictions to prepare for a "new normal."
Bioness Inc., a leading neuromodulation company, announced today two agreements to distribute new devices for patients experiencing neurological impairment. Through the agreements with Performance Enterprises and Aretech™, LLC, Bioness is now distributing the Dynavision D2™ Visuomotor Training System and the ZeroG™ Overground Gait and Balance Training System to rehabilitation centers and hospitals.
To detect "silent" or new cardiac abnormalities, all patients hospitalized for stroke should receive continuous cardiac rhythm monitoring (telemetry) for at least the first 24 hours after the stroke is detected, according to a Loyola University Health System study presented at the American Stroke Association's International Stroke Conference 2006.
Critical Outcome Technologies Inc. today announced positive results from the first phase of its HIV integrase inhibitor discovery program. These results provide novel intellectual property to the Company and further validation of the CHEMSAS® drug discovery technology.
› Verified 6 days ago
Dr. Emmanuel A Bayongan, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1400 S Dobson Rd, Mesa, AZ 85202 Phone: 480-543-2034 Fax: 480-512-6089 | |
Dr. Sanjeev Gopal, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6424 E Broadway Rd, 104-105, Mesa, AZ 85206 Phone: 602-802-8700 Fax: 602-802-8799 | |
Mouhsen H Alhakeem, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1400 S Dobson Road, Attn Amanda Gump/hospitalist, Mesa, AZ 85202 Phone: 480-412-6788 Fax: 480-412-6848 | |
Dr. Bindu Jayavelu, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 301 S Power Rd Ste 103, Mesa, AZ 85206 Phone: 480-325-7535 Fax: 480-325-7462 | |
Mr. Robert Bobek Arashahi, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5652 E Baseline Rd, Mesa, AZ 85206 Phone: 480-477-7166 | |
Mr. Robert P Tully, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 7525 E Broadway Rd, Ste 2, Mesa, AZ 85208 Phone: 480-981-9800 Fax: 480-985-9465 | |
Joshua D Cohen, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6750 E Baywood Ave, 301, Mesa, AZ 85206 Phone: 480-835-6100 Fax: 480-461-4261 |